The polymyxin resistance testing market is anticipated to be valued US$ 122.0 million in 2023. Over the course of the forecast period, the market is anticipated to grow at a 6.2% CAGR and reach US$ 222.5 million by 2033. A class of antibiotics known as polymyxins is used to treat serious infections brought on by Gram-negative bacteria that are resistant to multiple drugs, including strains that are resistant to other widely used antibiotics.
The emergence and spread of polymyxin-resistant bacteria, particularly due to the production of enzymes called carbapenemases, have raised concerns in healthcare settings. Effective detection and monitoring of polymyxin resistance are crucial to guide appropriate treatment decisions and prevent the further spread of resistant strains.
Get a Sample Copy of the Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-17621
The Polymyxin Resistance Testing market primarily consists of diagnostic tests and products designed to identify the presence of polymyxin resistance genes or enzymes in bacterial isolates. These tests help healthcare providers determine whether a particular strain of bacteria is susceptible or resistant to polymyxin antibiotics.
Antibiotic treatment individualized based on patient characteristics, including resistance profiles, is becoming more popular. Testing for polymyxin resistance enables medical professionals to choose the best antibiotic therapy with knowledge.
Diagnostic firms, molecular testing labs, and university research organizations are significant market participants in the polymyxin resistance testing industry. These businesses create and distribute a variety of test kits, reagents, and platforms for determining polymyxin resistance.
It’s crucial to keep in mind that the market for polymyxin resistance testing falls under the category of infectious disease diagnostics, which is somewhat specialized and may have a smaller market than areas like molecular diagnostics or testing for antibiotic susceptibility.
Key Takeaways:
- The polymyxin resistance testing industry in the United States is predicted to reach US$ 56.1 million by 2033, increasing at a 6.2% CAGR.
- The polymyxin resistance testing industry in the United Kingdom is estimated to reach a market value of US$ 7.4 million, expanding at a CAGR of 4.8% by 2033.
- During the forecast period, the polymyxin resistance testing industry in China is expected to reach a market value of US$ 19.0 million, securing a 7.5% CAGR.
- The polymyxin resistance testing industry in Japan is predicted to reach US$ 13.3 million by 2033, increasing at a 7.1% CAGR.
- South Korea’s polymyxin resistance testing industry is predicted to achieve a market value of US$ 5.6 million, rising at a 6.6% CAGR during the forecast period.
- With a CAGR of 6.4% from 2023 to 2033, the testing systems segment is expected to dominate the polymyxin resistance testing industry.
- With a CAGR of 6.4% from 2023 to 2033, the polymerase chain reaction (PCR) are expected to dominate the polymyxin resistance testing industry.
- With a CAGR of 7.0% from 2023 to 2033, the academic research institutions is expected to dominate the polymyxin resistance testing industry.
Key Players:
- Thermofisher Scientific
- Mast Group
- Liofilchem
- Rosco Diagnostica A/S
- bioMérieux SA
- Meridian
- Beckman Coulter
- Becton Dickenson Company
- Accelerate Diagnostics, Inc.
- Bruker
- EUCAST
- Generon S.p.A.
- Bio-Rad Laboratories
Key Developments:
- In June 2019, Thermo Fisher Scientific launches automated system for antimicrobial susceptibility testing in Europe
- In April 2022, Through its purchase of Specialised Diagnostic (San Jose, CA, USA), which focuses on quick AST solutions, bioMérieux has increased its commitment to combat AMR. A fast AST device that delivers phenotypic AST immediately from positive blood cultures was created by Specific.
Segmentation Analysis of the Polymyxin Resistance Testing Market
By Product:
- Testing Systems
- Test Kits Identification Panels
- Reagents Consumables
By Testing Methods:
- Broth Microdilution (BMD)
- Disk Diffusion
- Etest (Broth Microdilution + Disk Diffusion)
- Polymerase Chain Reaction (PCR)
By End User:
- Clinical Laboratories
- Academic Research Institutions
- Pharmaceutical/Biotech Companies
- Food Environmental Testing Laboratories
- Veterinary Diagnostic Laboratories
By Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- The Middle East Africa
Unlock Tailored Insights: Customize Your Report for Maximum Impact:
https://www.futuremarketinsights.com/customization-available/rep-gb-17621
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube